The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study

被引:47
作者
Wei, Kai-Ping [1 ,2 ]
Zhu, Feng-Cai [3 ]
Liu, Jian-Xun [4 ]
Yan, Ling [1 ,2 ]
Lu, Ying [1 ,2 ]
Zhai, Xiang-Jun [3 ]
Chang, Zhan-Jun [4 ]
Zeng, Ying [5 ]
Li, Jie [1 ,2 ]
Zhuang, Hui [1 ,2 ]
机构
[1] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Microbiol, 38 Xueyuan Rd, Beijing 100191, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Ctr Infect Dis, 38 Xueyuan Rd, Beijing 100191, Peoples R China
[3] Jiangsu Prov Ctr Dis Control & Prevent, Dept Infect Dis, Nanjing 210009, Jiangsu, Peoples R China
[4] Zhengzhou Municipal Ctr Dis Control & Prevent, Dept Major Projects, Zhengzhou 450053, Henan, Peoples R China
[5] Shenzhen Kangtai Biol Prod Co Ltd, Shenzhen 518057, Peoples R China
关键词
Hepatitis B virus; Mother-to-child transmission; Hepatitis B vaccine; Hepatitis B immunoglobulin; Antibody to hepatitis B surface antigen; INFANTS BORN; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION; SURFACE-ANTIGEN; RISK-FACTORS; VIRAL LOAD; IMMUNOPROPHYLAXIS; IMMUNIZATION; INFECTION; FAILURE;
D O I
10.1016/j.vaccine.2017.11.037
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background/aims: A birth dose of hepatitis B immunoglobulin (HBIG), in combination with hepatitis B vaccine (HepB), is recommended for infants born to hepatitis B surface antigen (HBsAg)-positive mothers. However, the optimal dosage of HBIG remains to be resolved. This prospective cohort study aimed to compare the efficacy of two dosages of HBIG combined with HepB to prevent mother-to-child transmission (MTCT) of HBV. Methods: From 2009 to 2011, we prospectively enrolled mother-infant pairs with positive maternal HBsAg in China. Infants were assigned to receive one dose of 100 IU or 200 IU HBIG within 12 h of birth according to maternal numbering, followed by completion of the 3-dose 10 mu g HepB series. At 7 months, post-vaccination serologic testing (PVST) was performed in 545 and 632 infants in 100 IU and 200 IU HBIG groups, respectively, among whom, 451 and 529 were followed up to 12 months. Results: Maternal and birth characteristics were comparable between infants in 100 IU and 200 IU HBIG groups. At 7 months, the rates of perinatal infection were 1.5% (8/545) and 1.9% (12/632) in 100 IU and 200 IU HBIG groups, respectively (p = .568). One non-responder infant in 200 IU HBIG group became newly infected at 12 months. The antibody to hepatitis B surface antigen (anti-HBs) positive rates were 98.5% (529/537) and 98.2% (609/620) in 100 IU and 200 IU HBIG groups at 7 months, respectively (p = .704), and the corresponding figures were 98.2% (431/439) and 97.1% (496/511) at 12 months (p = .266). The anti-HBs geometric mean concentrations were comparable between two groups at 7 months (707.95 mIU/mL vs. 602.56 mIU/mL, p = .062) and 12 months (245.47 mIU/mL vs. 229.09 mIU/mL, p = .407). Conclusions: One birth dose of 100 IU HBIG, combined with the HepB series, might be enough for preventing MTCT of HBV in infants born to HBsAg-positive mothers. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:256 / 263
页数:8
相关论文
共 33 条
[1]  
[Anonymous], 1991, MMWR Recomm Rep, V40, P1
[2]  
[Anonymous], AUSTR IMM HDB
[3]  
BEASLEY RP, 1983, HEPATOLOGY, V3, P135
[4]  
Benson Ruthie, 2012, Morbidity and Mortality Weekly Report, V61, P768
[5]  
Chinese Society of Hepatology Chinese Medical Association, 2015, Zhonghua Gan Zang Bing Za Zhi, V23, P888, DOI 10.3760/cma.j.issn.1007-3418.2015.12.002
[6]   Evaluation of the Abbott RealTime HBV DNA assay and comparison to the cobas AmpliPrep/Cobas TaqMan 48 assay in monitoring patients with chronic cases of hepatitis B [J].
Ciotti, Marco ;
Marcuccilli, Fabbio ;
Guenci, Tania ;
Prignano, Maria Grazia ;
Perno, Carlo Federico .
JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (04) :1517-1519
[7]   Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay [J].
Deguchi, M ;
Yamashita, N ;
Kagita, M ;
Asari, S ;
Iwatani, Y ;
Tsuchida, T ;
Iinuma, K ;
Mushahwar, IK .
JOURNAL OF VIROLOGICAL METHODS, 2004, 115 (02) :217-222
[8]  
GuiQiang W., 2015, GUIDELINES PREVENTIO, V7, P1, DOI 10.3969/j.issn.1674-7380.2015.03.001
[9]   A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection [J].
Han, Guo-Rong ;
Cao, Min-Kai ;
Zhao, Wei ;
Jiang, Hong-Xiu ;
Wang, Cui-Min ;
Bai, Shu-Fen ;
Yue, Xin ;
Wang, Gen-Ju ;
Tang, Xun ;
Fang, Zhi-Xun .
JOURNAL OF HEPATOLOGY, 2011, 55 (06) :1215-1221
[10]   Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan [J].
Hsu, HM ;
Lee, SC ;
Wang, MC ;
Lin, SF ;
Chen, DS .
VACCINE, 2001, 19 (20-22) :2825-2829